Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
31.00
-1.12 (-3.49%)
At close: Feb 21, 2025, 4:00 PM
31.04
+0.04 (0.13%)
After-hours: Feb 21, 2025, 4:57 PM EST
Tandem Diabetes Care Revenue
Tandem Diabetes Care had revenue of $243.97M in the quarter ending September 30, 2024, with 31.43% growth. This brings the company's revenue in the last twelve months to $854.35M, up 10.75% year-over-year. In the year 2023, Tandem Diabetes Care had annual revenue of $747.72M, down -6.68%.
Revenue (ttm)
$854.35M
Revenue Growth
+10.75%
P/S Ratio
2.37
Revenue / Employee
$355,980
Employees
2,400
Market Cap
2.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
Dec 31, 2019 | 362.31M | 178.44M | 97.05% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TNDM News
- 8 days ago - Tandem Diabetes Care Announces Upcoming Conference Presentations - Business Wire
- 5 weeks ago - Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
- 6 weeks ago - Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems - Business Wire
- 2 months ago - Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada - Business Wire
- 3 months ago - Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 3 months ago - Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance - Business Wire
- 4 months ago - Tandem Diabetes Care Announces Upcoming Conference Participation - Business Wire
- 5 months ago - Tandem Diabetes Care to Announce Third Quarter 2024 Financial Results on November 6, 2024 - Business Wire